Ib Kimyoung Co., Ltd. (339950) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Ib Kimyoung Co., Ltd. (339950:KRX), powered by AI.

Current Price
₩2,630
P/E Ratio
5.7
Market Cap
118.2B
Sector
Financial Services
What is the Ib Kimyoung Co., Ltd. stock price forecast?

Ib Kimyoung Co., Ltd. is currently trading at ₩2,630. View real-time AI analysis on Alpha Lenz.

What is Ib Kimyoung Co., Ltd. insider trading activity?

View the latest insider trading data for Ib Kimyoung Co., Ltd. on Alpha Lenz.

What is Ib Kimyoung Co., Ltd.'s P/E ratio?

Ib Kimyoung Co., Ltd.'s P/E ratio is 5.7.

Ib Kimyoung Co., Ltd.

KRX · 339950
₩2,630+10(+0.38%)Market closedKRX regular session 09:00–15:30 KST
Ask about Ib Kimyoung Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Ib Kimyoung Co., Ltd. trades at a P/E of 5.7 (undervalued) with strong ROE of 32.2%. 3Y revenue CAGR of 11.4% highlights clear growth momentum.

Ask for details

Company Overview

Ib Kimyoung Co., Ltd. is a notable name in the biotechnology and pharmaceuticals sector, primarily engaged in research, development, and commercialization of innovative therapeutic solutions. The company's core mission revolves around improving patient outcomes through cutting-edge biopharmaceutical products and technologies. Ib Kimyoung Co., Ltd. has carved a niche for itself by focusing on key therapeutic areas that address critical unmet medical needs, thus playing a pivotal role in advancing healthcare solutions. With a strong emphasis on research and development, the company invests significantly in exploring novel drug candidates and optimizing drug discovery processes. Its impact resonates across various dimensions of the healthcare industry, from providing groundbreaking treatments to enhancing the overall efficiency of healthcare delivery. In the financial markets, Ib Kimyoung Co., Ltd. serves as a crucial entity within the biopharmaceutical landscape, contributing to the dynamism of the sector. The company's innovations not only hold the potential to transform lives but also to influence market trends, fostering growth and sustainability in the healthcare domain.

CEO김석철
SectorFinancial Services
IndustryShell Companies
Employees317

Company Statistics

FY 2025

Profile

₩118,209,702,650Market Cap
₩119,488,397,130Revenue
44.95MShares Out
317Employees

Margins

71.16%Gross
32.77%EBITDA
15.96%Operating
20.90%Pre-Tax
16.84%Net

Valuation

5.71P/E
1.60P/B
0.99EV/Sales
2.94EV/EBITDA
4.10P/FCF

Growth (CAGR)

11.37%Rev 3Yr
14.81%Rev 5Yr
83.59%Op Inc 3Yr
36.11%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

18.39%ROA
32.19%ROE
23.51%ROIC

Financial Health

₩13,830,218,420Cash & Cash Equivalents
₩36,079,418,850Net Debt
70.37%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Ib Kimyoung Co., Ltd. (ticker: 339950) is a company listed on KRX in the Financial Services sector (Shell Companies). It has approximately 317 employees. Market cap is $118.2B.

The current price is ₩2,630 with a P/E ratio of 5.71x and P/B of 1.6x.

ROE is 32.19% and operating margin is 15.96%. Annual revenue is $119.5B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Ib Kimyoung Co., Ltd. (339950) Stock Forecast 2026 ₩2,630 — Price, Financials & Analyst Targets | Alpha Lenz